| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $9.4M | — | -45.9% |
| SG&A Expense | $5.8M | — | +2.6% |
| Operating Income | -$15.2M | — | +33.9% |
| Net Income | -$13.7M | — | +34.0% |
| EPS (Basic) | -$0.20 | — | +35.5% |
| EPS (Diluted) | -$0.20 | — | +35.5% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $8.4M | -76.6% | -71.2% |
| Short-term Investments | $101.2M | +54.8% | +46.6% |
| Current Assets | $113.4M | +7.1% | +13.1% |
| Total Assets | $152.4M | -9.2% | -24.1% |
| Current Liabilities | $4.1M | -41.7% | -42.1% |
| Total Liabilities | $4.3M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$14.4M | — | +6.8% |
| Investing Cash Flow | -$13.0M | — | +69.7% |
| Financing Cash Flow | $5K | — | — |
| -41.7% |
| Stockholders' Equity | $148.1M | -7.7% | -23.4% |